Myomo (NYSE:MYO) today said it appointed Dr. Harry Kovelman as chief medical officer, effective immediately.
Kovelman will be responsible for overseeing the company’s patient advocacy organization. He will work with commercial and government payer organizations to increase patient access to the MyoPro product line.
“I’m pleased to welcome Dr. Kovelman to Myomo as we continue to expand patient access to our life-changing technology, add to our clinical research, and educate additional medical professionals about the MyoPro product line. I’d also like to thank Dr. Brandon Green who has served in this role for the last four years and is fully supporting the transition in this chief medical officer position,” CEO Paul Gudonis said in a news release.
Kovelman has held numerous leadership roles at Ottobock Healthcare, Dynasplint Systems, Pacira Pharmaceuticals and Helius Medical Technologies.